Authors
Latest:
New Standards for First-to-Launch PlayersWhile COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
Latest:
E-Labeling: Change is UnderwayPriyanka Chaudhary and Vikram Shetty outline the current challenges and opportunities presented by e-labeling around the world.
Latest:
How Will COVID-19 Affect the Financing of Healthcare Provision Across the US?As providers and payers exert ever greater pressure on the pharma industry, will they force manufacturers to offer significant pricing concessions and will this become the new normal for the US healthcare system? Brett Gardiner reports.
Latest:
Leverage Compliance Activities to Drive Data-Driven SuccessXavier Duburcq describes how pharma leaders can convert compliance from a cost center to a critical success factor.
Latest:
FDA Expands Indication for Gilead’s Biktarvy for HIV With Suppressed Viral Loads, Pre-Existing ResistanceBiktarvy approved for expanded indication to include patients with HIV who have suppressed viral loads with known or suspected M184V/I resistance.
Latest:
Big Events Go Virtual: A Look Inside One TransformationThe transition from in-person was challenging, but meetings like DIA’s global event could explore formal hybrid models in the future.
Latest:
Preparing to Share Regulatory Data: 5 Practical TipsDuncan van Rijsbergen highlights key considerations for life sciences companies tackling data quality issues.
Latest:
Culture and Compliance: Building a Culture of Business EthicsAmid the limitations of traditional compliance programs that emphasize control measures, here are steps biopharma companies can implement in their own cultures to ensure they’re behaving and performing with integrity.
Latest:
Culture and Compliance: Building a Culture of Business EthicsAmid the limitations of traditional compliance programs that emphasize control measures, here are steps biopharma companies can implement in their own cultures to ensure they’re behaving and performing with integrity.
Latest:
Enterprise Leadership: Is Compliance Ripe for Disruption?Case study illustrates how compliance teams, in today’s climate, can foster innovation across an organization to help achieve corporate goals.
Latest:
Enterprise Leadership: Is Compliance Ripe for Disruption?Case study illustrates how compliance teams, in today’s climate, can foster innovation across an organization to help achieve corporate goals.
Latest:
Turning Safety and Regulatory to Business Driver with Natural Language ProcessingTo save time spent on manual reporting, pharmaceutical companies are turning to Natural Language Processing (NLP) which holds the combined potential for automating processes and enabling a deeper understanding of previously untapped data.
Latest:
Turning Safety and Regulatory to Business Driver with Natural Language ProcessingTo save time spent on manual reporting, pharmaceutical companies are turning to Natural Language Processing (NLP) which holds the combined potential for automating processes and enabling a deeper understanding of previously untapped data.
Latest:
How Oncologists are Coping with COVID-19Report highlights how oncology practices are becoming more virtual-oriented in light of the global pandemic.
Latest:
Strategic Realignment for a Better FutureIn adjusting to the long-term side-effects of the coronavirus pandemic, pharma companies will need to focus on change in three areas. Ben van der Schaaf and Aurelien Guichard report.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
How to REVAMP Sales and Marketing During a Pandemic for Pharma with Value-Driven ApproachWhile the COVID-19 pandemic has put a halt to in-person selling for pharma companies, it has a created a new opportunity for reps to rethink and adapt to new strategies.
Latest:
3 Digital Trends to Support Your Sales Teams Post-COVID-19As the world determines how best to function in a COVID-19 world, it is all but certain that some level of safety measures will continue for the foreseeable future.
Latest:
How Oncologists Cope with COVID-19The COVID-19 pandemic has created challenges across the entirety of the medical landscape. Oncologists and hematologists are just a few of many healthcare providers (HCPs) that have had to adjust to these challenges on the fly.
Latest:
COVID-19: Expanding Remote Patient Services during LockdownStephanie Hill looks at the efforts made by patient solutions providers in the UK to build and support services outside the hospital environment during the pandemic.
Latest:
Patient Information Labeling and COVID-19In recent months, many pharma businesses have pivoted to entirely new product lines against a backdrop of unprecedented disruption to the supply chain. Gurdip Singh provide pointers to ensure companies are ready to adapt to change.
Latest:
Who Pays for Specialty Medicines?Providers and patients fish for that delicate balance between access and abandonment.
Latest:
Risk-Based Monitoring: From the Road Less Traveled to Productivity SuperhighwayThe latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.
